Ignite Creation Date:
2024-05-06 @ 3:28 AM
Last Modification Date:
2024-10-26 @ 11:34 AM
Study NCT ID:
NCT02293096
Status:
TERMINATED
Last Update Posted:
2021-09-16
First Post:
2014-11-13
Brief Title:
Pharmacogenetic Prediction of Metoprolol Effectiveness
Sponsor:
University of Colorado Denver
Organization:
University of Colorado Denver
Study Overview
Official Title:
Pharmacogenetic Prediction of Metoprolol Effectiveness
Status:
TERMINATED
Status Verified Date:
2021-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was terminated due to the change in funding
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators will prospectively follow a population of patients with uncontrolled high blood pressure beginning metoprolol succinate therapy to determine the drug effect in an observational clinical trial The investigators will determine each individuals genotype for both CYP2D6 and Adrenoceptor Beta 1 ADRB1 Metabolomic markers will be identified to determine if specific metabolites are associated with drug response The investigators overall objective is to determine if genetics predicts metoprolol succinate response better than clinical factors such as age race body mass index dose and medication co-ingestion
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1K23GM110516-01 | NIH | None | httpsreporternihgovquickSearch1K23GM110516-01 |